where to inject ghk cu for face GHK-Cu: Sites and Rotation how much ghk cu to

10.1002/jor.20089 85 StrangS

The Phase 2 clinical trial showed roughly 2-3 kg more fat loss than placebo over 12 weeks, with no impact on blood sugar, insulin, IGF-1, or any hormonal marker

At the highest dose of 15mg, participants lost an average of 22.5% of their body weight over 72 weeks

In addition to being used for liquid medicine injections, this device is suitable for administering various medications, including growth hormone, liquid medicine, antibiotics, interferon, beauty products, biochemical emergency prevention, hemostatic pain relief, first aid for heart disease, detoxification, antipyretic analgesics, anesthetic sedatives, and more

In hepatocytes and adipocytes it reduces the activity of key lipogenic enzymes: Acetyl-CoA carboxylase (ACC) , a key step in fatty acid synthesis Fatty acid synthase (FAS) , the enzyme creating long chains of fatty acids Lipoprotein lipase (LPL) in adipocytes, reduces uptake of circulating triglycerides into fat cells Imagine it as turning valves in a pipeline, you close the inflow (lipogenesis), open the outflow (lipolysis)

Standard Cagrilintide Monotherapy Protocol Phase 1: Initiation (Weeks 1-2) Dose: 0.6 mg once weekly Goal: Establish tolerance to amylin activation Expected effects: Mild appetite reduction, possible mild nausea Adjustments: Extend this phase if significant GI effects occur Phase 2: First Escalation (Weeks 3-4) Dose: 1.2 mg once weekly Goal: Increase therapeutic effect Expected effects: Notable appetite suppression, improved satiety Adjustments: May stay at this dose if excellent results achieved Phase 3: Second Escalation (Weeks 5-8) Dose: 2.4 mg once weekly Goal: Approach optimal therapeutic range Expected effects: Significant appetite control, steady weight loss Adjustments: Many researchers find this dose optimal long-term Phase 4: Optimization (Weeks 9-12) Dose: 3.0 mg once weekly Goal: Maximize therapeutic benefit Expected effects: Peak appetite suppression Adjustments: Only escalate if 2.4 mg insufficient and well-tolerated Phase 5: Maintenance (Week 13+) Dose: 3.0-4.5 mg once weekly Goal: Sustain long-term effects Expected effects: Stable appetite control and weight management Adjustments: Find minimum effective dose for maintenance Cagrilintide Dosage with Retatrutide: Combination Protocol When combining cagrilintide with retatrutide, a more conservative escalation approach minimizes overlapping side effects: Weeks 1-2: Single Agent Start Cagrilintide: 0.6 mg weekly Retatrutide: None (or 0.6 mg if starting both) Rationale: Establish tolerance to one compound first Weeks 3-4: Gentle Combination Cagrilintide: 0.6-1.2 mg weekly Retatrutide: 2 mg weekly Rationale: Introduce second compound at low dose Weeks 5-8: Dual Escalation Cagrilintide: 1.2-2.4 mg weekly Retatrutide: 4 mg weekly Rationale: Gradually increase both compounds Weeks 9-12: Therapeutic Range Cagrilintide: 2.4 mg weekly Retatrutide: 6-8 mg weekly Rationale: Approach optimal combination dosing Weeks 13+: Optimized Maintenance Cagrilintide: 2.4-3.0 mg weekly Retatrutide: 8-12 mg weekly Rationale: Maintain therapeutic effects long-term Researchers can access properly dosed cagrilintide 10mg vials that allow flexible dosing across this range